Meta AnalysisID 642
紫锥菊预防或治疗COVID-19及其他人类呼吸道感染的快速评价
CRD42020186339
The primary objective of this rapid review is to assess the effects of Echinacea supplementation in reducing the incidence, duration and severity of acute COVID-19, or other upper or lower respiratory tract infections in
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 642
- Evidence Id
- 9200
- Core Evidence Id
- 9200
- Source Meta Analysis Id
- 621
- Herb2 Meta Analysis Id
- HBMA000621
- Crd Id
- CRD42020186339
- Title
- A rapid review of Echinacea for the prevention or treatment of COVID-19 and other respiratory tract infections in humans
- Review Question
- The primary objective of this rapid review is to assess the effects of Echinacea supplementation in reducing the incidence, duration and severity of acute COVID-19, or other upper or lower respiratory tract infections in adults when used as a preventive supplement or as a therapy. The secondary objective is to assess any evidence that Echinacea supplementation could increase the risk of cytokine storms, through an assessment of the impact on cytokine levels as seen in human clinical trials.
- Study Type Included
- Inclusion criteria: prospective human clinical trials. Exclusion criteria: systematic reviews, observational research, case reports, in vitro studies, animal studies, and pharmacological studies.
- Condition Being Studied
- In response to the 2020 COVID-19 pandemic, the primary focus of this review is acute upper and lower respiratory tract infections caused by 2019-nCoV. The effect of the intervention on other coronavirus infections will also be evaluated as a form of indirect evidence. The coronaviruses commonly associated with severe respiratory disease and mortality such as SARS-CoV and MERS-CoV are of greatest interest, followed by other coronavirus infections (e.g. HCoV 229E, OC43, NL63, HUK1) that typically cause milder illnesses such as the common cold, or bronchitis, and finally, respiratory infections, the cause of which is undetermined, but which is likely to be viral, including coronavirus.
- Participant
- Inclusion criteria: adults of any gender with respiratory tract infections or healthy adults being assessed for the prevention of respiratory tract infections. Exclusion criteria: pediatric populations.
- Animal
- Human Disease Modelled
- Intervention
- Oral supplementation of Echinacea, alone or in combination with other herbs or nutrients.
- Comparator Control
- No treatment, other nutraceutical or usual care active treatments, or placebo.
- Main Outcome
- The prevention of respiratory tract illness. The treatment of respiratory tract infections. The risk of a negative impact on cytokines, cytokine storms, or cytokine release syndrome. Measures of effect For studies evaluating the prevention of illness: incidence rates of respiratory tract infections. For studies evaluating the treatment of respiratory tract infections: duration of illness. For studies assessing risk of a negative impact on cytokines: changes in the levels of interferons, interleukins, colony-stimulating factors or tumor necrosis factors; and the incidence of cytokine storms, or cytokine release syndrome.
- Outcome Measure
- Additional Outcome
- Studies evaluating the treatment of respiratory tract infections: the need for medication, the number of days in hospital, quality of life, and mortality. Measures of effect As above.
- Study Method
- Epidemiologic, Intervention, Prevention, Systematic review, Other
- Keyword
- Adjuvants, Immunologic; Adult; Biological Products; Coronavirus; Coronavirus Infections; COVID-19; Cytokines; Dietary Supplements; Echinacea; Humans; Incidence; Primary Prevention; Public Health; Respiratory Tract Infections; Treatment Outcome
- Contact
- Monique Aucoin [email protected]
- Organisational Affiliation
- Canadian College of Naturopathic Medicine www.ccnm.edu
- Funding Source
- This project is currently unfunded, but if funding is procured in the future, we will prioritize non-industry sources if possible. If not, we will ensure that any apparent or actual conflicts of interest are transparently reported and that the funding body will have no input on the design, execution, or reporting of the project and will have no input as to the choice of where or if to publish/disseminate our findings
- Other Selection Criteria
- Final Publication
- Aucoin M, Cooley K, Saunders PR, Carè J, Anheyer D, Medina DN, Cardozo V, Remy D, Hannan N, Garber A. The effect of Echinacea spp. on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review. Advances in integrative medicine. 2020 Dec 1;7(4):203-17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395221/
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Australia, Canada, Germany
- Review Stage
- Review Completed published
- First Submission Date
- 2020-05-19
- Registration Date
- 2020-05-20
- Anticipated Start Date
- 2020-05-01
- Anticipated Completion Date
- 2020-06-20
- Title Cn
- 紫锥菊预防或治疗COVID-19及其他人类呼吸道感染的快速评价
- Title En
- A rapid review of Echinacea for the prevention or treatment of COVID-19 and other respiratory tract infections in humans
- Bilingual Status
- complete